Emerging Treatments | Lung Cancer - World Medical Innovation Forum

Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer death. While much therapeutic development is underway, insights from lung cancer research may also benefit other solid tumors. This session will explore the evolving treatment landscape: including bispecific antibodies (e.g., PD-1 x VEGF, EGFR x MET, PD-1 x TIGIT); novel ADCs (e.g. TROP-2 class of agents), checkpoint inhibitors beyond PD-1/-L1 and CTLA-4, such as TIGIT, LAG-3, and TIM-3; and late-stage cancer vaccines.

Moderators

Tim Anderson, MD,

Pharmaceutical Analyst, BofA Securities

Alec Stranahan,

SMid-Cap Biotech Analyst, BofA Securities

Speaker

Justin Gainor, MD

Director, Center for Thoracic Cancers Program, Massachusetts General Hospital;

Associate Professor of Medicine, Harvard Medical School

Rebecca Heist, MD,

Associate Director of Clinical Research, Mass General Cancer Center;

Professor of Medicine, Harvard Medical School

Zofia Piotrowska, MD,

Massachusetts General Hospital;

Assistant Professor of Medicine, Harvard Medical School